Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456971 | 0.80 | MKNK1 (0.37) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL31165789 | 0.77 | PDE4A (0.48) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL17121438 | 0.77 | PDE4A (0.48) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL22189751 | 0.73 | AKT1 (0.48) | PDE4APDE4BPDE4DPDE4CAKT1 | |
| SCHEMBL12196972 | 0.73 | PDE4A (0.48) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL1746576 | 0.72 | MKNK1 (0.49) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL15767249 | 0.72 | PDE4A (0.43) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL2066630 | 0.70 | CA1 (0.36) | PDE4AMKNK1PDE4BPDE4DPDE4C | |
| SCHEMBL2068562 | 0.70 | PDE4B (0.35) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL14781543 | 0.69 | PDE4A (0.48) | PDE4AMKNK1PDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2385946-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND TUERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-8040450-B2 | Liquid crystal electro-optic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010070238-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | PDE4A 1427/4885MKNK1 200/4885PDE4B 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.